Loading...
Please wait, while we are loading the content...
Similar Documents
Heterologous ChAdOx1 nCoV-19/BNT162b2 Prime-Boost Vaccination Induces Strong Humoral Responses among Health Care Workers
| Content Provider | MDPI |
|---|---|
| Author | Maximilian, Töllner Florian, Kälble Caner, Süsal Benning, Louise Hidmark, Asa Schaier, Matthias Nusshag, Christian Reichel, Paula Buylaert, Mirabel Grenz, Julia Ponath, Gerald Klein, Katrin Zeier, Martin Schnitzler, Paul Morath, Christian Speer, Claudius |
| Copyright Year | 2021 |
| Description | Despite limited data on safety and immunogenicity, heterologous prime-boost vaccination is currently recommended for individuals with ChAdOx1 nCoV-19 prime immunization in certain age groups. In this prospective, single-center study we included 166 health care workers from Heidelberg University Hospital who received either heterologous ChAdOx1 nCoV-19/BNT162b2, homologous BNT162b2 or homologous ChAdOx1 nCoV-19 vaccination between December 2020 and May 2021. We measured anti-S1 IgG, SARS-CoV-2 specific neutralizing antibodies, and antibodies against different SARS-CoV-2 fragments 0–3 days before and 19–21 days after boost vaccination. Before boost, 55/70 (79%) ChAdOx1 nCoV-19-primed compared with 44/45 (98%) BNT162b2-primed individuals showed positive anti-S1 IgG with a median (IQR) anti-S1 IgG index of 1.95 (1.05–2.99) compared to 9.38 (6.26–17.12). SARS-CoV-2 neutralizing antibodies exceeded the threshold in 24/70 (34%) of ChAdOx1 nCoV-19-primed and 43/45 (96%) of BNT162b2-primed individuals. After boosting dose, median (IQR) anti-S1 IgG index in heterologous ChAdOx1 nCoV-19/BNT162b2 vaccinees was 116.2 (61.84–170), compared to 13.09 (7.03–29.02) in homologous ChAdOx1 nCoV-19 and 145.5 (100–291.1) in homologous BNT162b2 vaccinees. All boosted vaccinees exceeded the threshold for neutralization, irrespective of their vaccination scheme. Vaccination was well-tolerated overall. We show that heterologous ChAdOx1 nCoV-19/BNT162b2 vaccination is safe and induces a strong and broad humoral response in healthy individuals. |
| Starting Page | 857 |
| e-ISSN | 2076393X |
| DOI | 10.3390/vaccines9080857 |
| Journal | Vaccines |
| Issue Number | 8 |
| Volume Number | 9 |
| Language | English |
| Publisher | MDPI |
| Publisher Date | 2021-08-04 |
| Access Restriction | Open |
| Subject Keyword | Vaccines Infectious Diseases Covid-19 Covid-19 Vaccination Heterologous Vaccination Humoral Response Mrna Vaccine Bnt162b2 Adenovirus-vectored Vaccine Chadox1 Ncov-19 Sars-cov-2 |
| Content Type | Text |
| Resource Type | Article |
